LT3664B - Sustained release drug formation containing a tramadol salt - Google Patents
Sustained release drug formation containing a tramadol salt Download PDFInfo
- Publication number
- LT3664B LT3664B LTIP2033A LTIP2033A LT3664B LT 3664 B LT3664 B LT 3664B LT IP2033 A LTIP2033 A LT IP2033A LT IP2033 A LTIP2033 A LT IP2033A LT 3664 B LT3664 B LT 3664B
- Authority
- LT
- Lithuania
- Prior art keywords
- weight
- release
- tablet
- active ingredient
- tablets
- Prior art date
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical class COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title abstract description 17
- 229940079593 drug Drugs 0.000 title description 14
- 238000013268 sustained release Methods 0.000 title description 3
- 239000012730 sustained-release form Substances 0.000 title description 3
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000011159 matrix material Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 238000013270 controlled release Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229920003086 cellulose ether Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 229960004380 tramadol Drugs 0.000 claims description 5
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 58
- 239000000203 mixture Substances 0.000 description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 229960003107 tramadol hydrochloride Drugs 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000008119 colloidal silica Substances 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 239000000945 filler Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011229 interlayer Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940038613 tramadol hydrochloride 200 mg Drugs 0.000 description 2
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4329794A DE4329794C2 (de) | 1993-09-03 | 1993-09-03 | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP2033A LTIP2033A (en) | 1995-03-27 |
| LT3664B true LT3664B (en) | 1996-01-25 |
Family
ID=6496771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP2033A LT3664B (en) | 1993-09-03 | 1994-09-02 | Sustained release drug formation containing a tramadol salt |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5601842A (enExample) |
| EP (1) | EP0642788B1 (enExample) |
| JP (1) | JP3954117B2 (enExample) |
| KR (1) | KR100325494B1 (enExample) |
| CN (1) | CN1092956C (enExample) |
| AT (1) | ATE166575T1 (enExample) |
| AU (1) | AU671384B2 (enExample) |
| BR (1) | BR9403030A (enExample) |
| CA (1) | CA2131350C (enExample) |
| CO (1) | CO4290295A1 (enExample) |
| CZ (1) | CZ288832B6 (enExample) |
| DE (2) | DE4329794C2 (enExample) |
| DK (1) | DK0642788T3 (enExample) |
| EC (1) | ECSP941148A (enExample) |
| ES (1) | ES2119034T3 (enExample) |
| FI (1) | FI113336B (enExample) |
| HK (1) | HK1010447A1 (enExample) |
| HU (1) | HU215955B (enExample) |
| IL (1) | IL109800A (enExample) |
| LT (1) | LT3664B (enExample) |
| MY (1) | MY111754A (enExample) |
| PE (1) | PE10195A1 (enExample) |
| PL (1) | PL177315B1 (enExample) |
| RU (1) | RU2138253C1 (enExample) |
| SI (1) | SI0642788T1 (enExample) |
| UA (1) | UA26455C2 (enExample) |
| UY (1) | UY23804A1 (enExample) |
| ZA (1) | ZA946775B (enExample) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
| IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
| US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
| US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| DE19530575A1 (de) * | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
| GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
| EP0888111B1 (en) * | 1996-03-08 | 2003-05-21 | Nycomed Danmark A/S | Modified release multiple-units dosage composition |
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| DE19712398A1 (de) * | 1997-03-25 | 1998-10-01 | Gruenenthal Gmbh | Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel |
| AU8293498A (en) * | 1997-07-02 | 1999-01-25 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
| US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
| US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
| DE29818454U1 (de) * | 1998-10-15 | 1999-01-14 | Euroceltique S.A., Luxemburg/Luxembourg | Opioid-Analgetikum |
| WO2000040205A2 (en) * | 1999-01-05 | 2000-07-13 | Copley Pharmaceutical Inc. | Sustained release formulation with reduced moisture sensitivity |
| DE19901686A1 (de) * | 1999-01-18 | 2000-07-20 | Gruenenthal Gmbh | Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung |
| DE19901692C2 (de) * | 1999-01-18 | 2002-06-20 | Gruenenthal Gmbh | Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes |
| DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| BR0013825A (pt) * | 1999-08-31 | 2002-07-23 | Gruenenthal Chemie | Formas de apresentação de tramadol |
| ES2374717T3 (es) | 1999-10-29 | 2012-02-21 | Euro-Celtique S.A. | Formulaciones de hidrocodona de liberación controlada. |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| SK285128B6 (sk) * | 1999-12-28 | 2006-07-07 | Zentiva, A. S. | Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy |
| RU2165922C1 (ru) * | 2000-07-19 | 2001-04-27 | Государственный научно-исследовательский институт органической химии и технологии | Способ получения трамадола |
| ES2228789T3 (es) * | 2000-09-22 | 2005-04-16 | Smb Technology | Composicion oral de tramadol en forma de granulados para tomar una vez por dia. |
| HUP0301177A3 (en) * | 2000-09-29 | 2006-07-28 | Solvay Pharm Bv | Ion-strength independent sustained release pharmaceutical formulation |
| AU2002227383B2 (en) | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| RU2174836C1 (ru) * | 2000-12-15 | 2001-10-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция, обладающая анальгезирующим действием |
| DE10108122A1 (de) | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Arzneimittel auf Basis von Tramadol |
| DE60211689T2 (de) | 2001-03-16 | 2007-01-11 | DMI Biosciences, Inc., Englewood | Verwendung von Tramadol zur Verzögerung der Ejakulation |
| US20110104214A1 (en) * | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| US20060099249A1 (en) * | 2002-02-21 | 2006-05-11 | Pawan Seth | Modified release formulations of at least one form of tramadol |
| US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
| JP2005526079A (ja) * | 2002-03-15 | 2005-09-02 | サイプレス バイオサイエンス， インコーポレイテッド | 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤 |
| AU2003215671A1 (en) * | 2002-03-22 | 2003-10-08 | Cilag Ag | Sustained release formulation of tramadol |
| US7410965B2 (en) | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| DE10224108A1 (de) * | 2002-05-29 | 2004-01-29 | Grünenthal GmbH | 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung |
| US7776314B2 (en) * | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20050020613A1 (en) * | 2002-09-20 | 2005-01-27 | Alpharma, Inc. | Sustained release opioid formulations and method of use |
| US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| EP1592453A1 (en) * | 2003-01-28 | 2005-11-09 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
| DE10333835A1 (de) * | 2003-07-24 | 2005-03-10 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung |
| WO2005016313A1 (de) * | 2003-08-06 | 2005-02-24 | Grünenthal GmbH | Gegen missbrauch gesicherte darreichungsform |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032051A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| US20050089558A1 (en) * | 2003-10-28 | 2005-04-28 | Alamo Pharmaceuticals, Llc | Compositions and methods for the co-formulation and administration of tramadol and propoxyphene |
| DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| ITMI20050391A1 (it) * | 2005-03-11 | 2006-09-12 | Ph & T S P A | Formulazioni a rilascio controllato di alfuzosin |
| BRPI0612802A2 (pt) * | 2005-07-07 | 2010-11-30 | Farnam Co Inc | composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis |
| RU2008113439A (ru) | 2005-09-09 | 2009-10-20 | Лабофарм Инк. (CA) | Композиции с замедленным высвобождением лекарственного средства |
| JP5269595B2 (ja) * | 2005-09-09 | 2013-08-21 | アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー | １日１回投与用トラゾドン組成物 |
| US20090104266A1 (en) * | 2005-09-15 | 2009-04-23 | Tobias Jung | 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation |
| US8691272B2 (en) * | 2005-12-30 | 2014-04-08 | Intelgenx Corp. | Multilayer tablet |
| US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| WO2008011595A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
| DE102006044694A1 (de) * | 2006-09-22 | 2008-03-27 | Krewel Meuselbach Gmbh | Perorale feste Schmerzmittelzubereitung |
| EP2120570B1 (en) | 2007-02-12 | 2012-05-16 | DMI Biosciences, Inc. | Treatment of comorbid premature ejaculation and erectile dysfunction |
| MX2009008511A (es) | 2007-02-12 | 2010-01-20 | Dmi Biosciences Inc | Reduccion de efectos secundarios de tramadol. |
| DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| EP2203166B1 (en) * | 2007-10-16 | 2015-05-06 | Paladin Labs Inc. | Bilayer composition for the sustained release of acetaminophen and tramadol |
| AU2008338207A1 (en) | 2007-12-17 | 2009-06-25 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
| EP2249811A1 (en) * | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
| NZ588863A (en) * | 2008-05-09 | 2012-08-31 | Gruenenthal Chemie | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
| AU2009327312A1 (en) * | 2008-12-16 | 2011-08-04 | Labopharm Europe Limited | Misuse preventative, controlled release formulation |
| PE20121067A1 (es) | 2009-07-22 | 2012-09-05 | Gruenenthal Chemie | Forma de dosificacion de liberacion controlada extruida por fusion en caliente |
| CN102573806B (zh) | 2009-07-22 | 2015-02-25 | 格吕伦塔尔有限公司 | 用于对氧化敏感的阿片类物质的抗破坏剂型 |
| US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
| US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
| ES2606227T3 (es) * | 2010-02-03 | 2017-03-23 | Grünenthal GmbH | Preparación de una composición farmacéutica en polvo mediante una extrusora |
| AU2011252040C1 (en) | 2010-05-10 | 2015-04-02 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| WO2012003968A1 (en) | 2010-07-06 | 2012-01-12 | Grünenthal GmbH | Novel gastro- retentive dosage forms comprising a gaba analog and an opioid |
| PL2611426T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie |
| PL2611425T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Odporna na ingerencję postać dawki zawierająca polimer anionowy |
| US20120202838A1 (en) * | 2010-11-04 | 2012-08-09 | Abbott Laboratories | Drug formulations |
| ES2655900T3 (es) | 2011-07-29 | 2018-02-22 | Grünenthal GmbH | Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento |
| HRP20171458T1 (hr) | 2011-07-29 | 2017-11-17 | Grünenthal GmbH | Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka |
| EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| PT2838512T (pt) | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping) |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| EP3003279A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
| MX368846B (es) | 2013-07-12 | 2019-10-18 | Gruenenthal Gmbh | Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo. |
| EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| JP2017516789A (ja) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
| AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5492631A (en) * | 1977-12-27 | 1979-07-23 | Kowa Co | Analgestic |
| US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
| EP0147780A3 (en) * | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| FR2618073B1 (fr) * | 1987-07-16 | 1990-09-07 | Pf Medicament | Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation |
| DE3830353A1 (de) * | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| JPH04217925A (ja) * | 1990-03-27 | 1992-08-07 | Nippon Saafuakutanto Kogyo Kk | 新規な解熱消炎鎮痛剤組成物 |
| IL119660A (en) * | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| DE4315525B4 (de) * | 1993-05-10 | 2010-04-15 | Euro-Celtique S.A. | Pharmazeutische Zusammensetzung |
-
1993
- 1993-09-03 DE DE4329794A patent/DE4329794C2/de not_active Expired - Fee Related
-
1994
- 1994-05-26 IL IL10980094A patent/IL109800A/xx not_active IP Right Cessation
- 1994-07-11 UY UY23804A patent/UY23804A1/es not_active IP Right Cessation
- 1994-07-19 PE PE1994246995A patent/PE10195A1/es not_active IP Right Cessation
- 1994-07-22 MY MYPI94001903A patent/MY111754A/en unknown
- 1994-08-24 DK DK94113192T patent/DK0642788T3/da active
- 1994-08-24 DE DE59406075T patent/DE59406075D1/de not_active Expired - Lifetime
- 1994-08-24 SI SI9430142T patent/SI0642788T1/xx unknown
- 1994-08-24 EP EP94113192A patent/EP0642788B1/de not_active Expired - Lifetime
- 1994-08-24 AT AT94113192T patent/ATE166575T1/de active
- 1994-08-24 ES ES94113192T patent/ES2119034T3/es not_active Expired - Lifetime
- 1994-08-25 EC EC1994001148A patent/ECSP941148A/es unknown
- 1994-08-29 HU HU9402478A patent/HU215955B/hu unknown
- 1994-09-01 BR BR9403030A patent/BR9403030A/pt not_active Application Discontinuation
- 1994-09-01 CA CA002131350A patent/CA2131350C/en not_active Expired - Lifetime
- 1994-09-01 PL PL94304860A patent/PL177315B1/pl unknown
- 1994-09-01 JP JP20895794A patent/JP3954117B2/ja not_active Expired - Lifetime
- 1994-09-01 RU RU94032150A patent/RU2138253C1/ru active
- 1994-09-01 KR KR1019940021959A patent/KR100325494B1/ko not_active Expired - Lifetime
- 1994-09-02 UA UA94095777A patent/UA26455C2/uk unknown
- 1994-09-02 CN CN94115648A patent/CN1092956C/zh not_active Expired - Lifetime
- 1994-09-02 LT LTIP2033A patent/LT3664B/lt not_active IP Right Cessation
- 1994-09-02 ZA ZA946775A patent/ZA946775B/xx unknown
- 1994-09-02 FI FI944035A patent/FI113336B/fi not_active IP Right Cessation
- 1994-09-02 CO CO94039369A patent/CO4290295A1/es unknown
- 1994-09-02 AU AU72803/94A patent/AU671384B2/en not_active Expired
- 1994-09-05 CZ CZ19942140A patent/CZ288832B6/cs not_active IP Right Cessation
-
1996
- 1996-01-16 US US08/585,741 patent/US5601842A/en not_active Expired - Lifetime
-
1998
- 1998-09-28 HK HK98111000A patent/HK1010447A1/xx not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4389393B1 (enExample) | 1982-03-26 | 1985-10-22 |
Non-Patent Citations (2)
| Title |
|---|
| FORD JL ET AL.: "Importance of drug type tablet shape and added diluents on drug release kinetics from hydroxypropyl methyl cellulose matrix tablets", INT. J. PHARM., 1987, pages 223 |
| LAPIDUS H, LORDI NG: "Drug release from compressed hydrophilic matrices", J PHARM SCI., 1968, pages 1292 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3664B (en) | Sustained release drug formation containing a tramadol salt | |
| HK1010447B (en) | Tramadol salt containing medicaments with sustained release of the active ingredient | |
| US8637512B2 (en) | Formulations and method of treatment | |
| JP4744142B2 (ja) | ラモトリギンを含む徐放性処方 | |
| JP2005506367A (ja) | 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬 | |
| AU2002322964B2 (en) | Dosage forms having prolonged active ingredient release | |
| WO2008128740A1 (en) | Titration of tapentadol | |
| EP1473030B1 (en) | Extended release Venlafaxine tablet formulation | |
| MXPA05001127A (es) | Formulacion de bicifadina. | |
| EP1763338B1 (en) | Oral sustained release formulation of tedisamil with gastric retention properties | |
| WO2003082261A1 (en) | Extended release venlafaxine formulations | |
| KR20060118481A (ko) | 벤라팩신의 서방성 정제 제제 | |
| CN1172429A (zh) | 使用从高等植物中可得到的粉末状水解胶体树胶的持续释放药物运送体系 | |
| KR20080059212A (ko) | 3-(2-디메틸아미노메틸 사이클로헥실) 페놀 지연 제형 | |
| US8450349B2 (en) | Long acting dual release product containing carbinoxamine and pseudoephedrine | |
| WO2003057198A1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
| RU2325905C2 (ru) | Содержащее 3-(3-диметиламино-1-этил-2-метилпропил)фенол лекарственное средство с замедленным высвобождением действующего вещества | |
| AU2003285739B2 (en) | Extended release venlafaxine tablet formulation | |
| WO2008038106A1 (en) | Venlafaxine extended release formulations | |
| HK1070821B (en) | Extended release venlafaxine tablet formulation | |
| HK1068539B (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
| IL159780A (en) | Venlfaxine tablet for prolonged release |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Expiry of a patent |
Effective date: 20140902 |